| Literature DB >> 33372694 |
Giovanni Peretto1,2,3, Federica Barzaghi2,4, Maria Pia Cicalese2,4, Chiara Di Resta3,5, Massimo Slavich6, Sara Benedetti7, Sara Giangiobbe8, Stefania Rizzo9, Anna Palmisano2,3,10, Antonio Esposito2,3,10, Francesco De Cobelli3,10, Simone Gulletta1, Cristina Basso9, Giorgio Casari3,5, Alessandro Aiuti3,4, Paolo Della Bella1,3, Simone Sala1,2.
Abstract
We present, to our knowledge, the first case of immunosuppressive therapy (IST) application in a 12-year-old child with arrhythmogenic inflammatory cardiomyopathy resulting from the overlap between autoimmune myocarditis and primary arrhythmogenic cardiomyopathy. Indication to off-lable IST was compelling, because of recurrent drug-refractory ventricular arrhythmias (VAs). We show that IST was feasible, safe, and effective on multiple clinical endpoints, including symptoms, VA recurrences, and T-troponin release. Remarkably, all diagnostic and therapeutic strategies were worked out by a dedicated multidisciplinary team, including specialized pediatric immunologists.Entities:
Keywords: ARVC; childhood; immunosuppressive therapy; multidisciplinary; myocarditis; pediatric; ventricular arrhythmias
Mesh：
Substances：
Year: 2021 PMID： 33372694 DOI： 10.1111/pace.14153
Source DB: PubMed Journal: Pacing Clin Electrophysiol ISSN： 0147-8389 Impact factor: 1.976